ibrutinib venetoclax for cll
Published 4 years ago • 1.2K plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:16
dr. wierda on ibrutinib plus venetoclax in cll
-
2:12
dr. brander on the safety and efficacy of ibrutinib/venetoclax in cll
-
6:38
ibrutinib venetoclax for frontline cll
-
1:36
dr. logan discusses ibrutinib plus venetoclax in cll
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
1:07
ibrutinib plus venetoclax as a treatment option for cll
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
4:07
management of cll progression after ibrutinib
-
2:21
captivate: ibrutinib and venetoclax in cll
-
1:53
achieving undetectable mrd with ibrutinib plus venetoclax for cll
-
1:31
dr. smith on the rationale behind the fixed duration trial for ibrutinib/venetoclax in cll
-
0:54
dr. davids discusses ongoing research with ibrutinib plus venetoclax in cll
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
6:14
ibrutinib plus venetoclax for treatment of cll (chronic lymphocytic leukemia) - asco 2022
-
1:47
ash cll highlights: ibrutinib-venetoclax combination & undetectable mrd in ighv-mutated patients
-
0:56
dr. chavez discusses ibrutinib plus venetoclax in cll
-
1:25
dr. rogers discusses obinutuzumab, ibrutinib, and venetoclax combination in cll
-
5:54
updates from captivate: ibrutinib and venetoclax for cll